These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7730498)

  • 1. Serotonin-dopamine antagonists and treatment of negative symptoms.
    Carpenter WT
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):30S-35S. PubMed ID: 7730498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of serotonin in antipsychotic drug action.
    Meltzer HY
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?
    Miyake N; Miyamoto S; Jarskog LF
    Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):122-33. PubMed ID: 23006237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.
    Borison RL
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):24S-29S. PubMed ID: 7537285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone: an analysis of the first three years in general use.
    Gutierrez-Esteinou R; Grebb JA
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.